Illumina is Our Primary Genomics Investment

Illumina (ILMN) has been doing well lately, so I thought it was time to do another ILMN related posting. A few days ago on 02012.09.11 Illumina issued three press releases that I thought were good press releases.

"Illumina Launches TruSightTM Targeted Sequencing Content Sets"

"Designed by recognized experts at leading institutions, the content sets offer cost-effective, streamlined, targeted sequencing for specific genetic diseases or conditions."

"Illumina Announces Expedited Individual Genome Sequencing Service (IGS)"

"Illumina has long believed that sequencing will become a mainstream practice in the clinical setting. By delivering a whole human genome in as little as two weeks, we have taken significant strides towards that goal," said Illumina President and CEO Jay Flatley.

"Illumina and Partners HealthCare Announce Alliance to Introduce Next-Generation Sequencing Clinical Interpretation and Reporting Tools"

"Illumina and Partners HealthCare share a vision of better patient care through genomics," said Matt Posard, Senior Vice President and General Manager of Illumina’s Translational and Consumer Genomics business. "This alliance highlights our commitment to a collaborative model that will establish the new standard in NGS clinical-based applications and enable a truly integrated, high-quality solution."

ILMN closed yesterday (02012.09.13) at $46.48. 52-week range: $25.57 - $55.39.